EX-99.1 2 tm2531255d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 RETRACTABLE TECHNOLOGIES, INC. RESULTS FOR THE PERIODS ENDED SEPTEMBER 30, 2025 LITTLE ELM, TEXAS, November 14, 2025 - Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $10.1 million for the third quarter of 2025 and an operating loss of $3.7 million for the period, as compared to total net sales for the same period last year of $10.3 million and an operating loss of $5.1 million. For the first nine months of the year, net sales were $28.8 million and operating losses were $13.5 million as compared to 2024 net revenues of $24.0 million and operating losses of $13.9 million. Tariffs continue to have a material impact on our results of operation and financial position. The tariff rate on needles and syringes imported from China as of September 30, 2025 was 130% and the rate on other products imported from China was 30%. We spent $2.3 million on tariffs in the first nine months of 2025. We are working to lessen the financial impact of tariffs and have shifted to a larger proportion production to our U.S. facility. In the first nine months of 2025, 38.3% of our products were manufactured in …
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
Retractable Technologies, Inc
RVPNYSE_AMERICANEQUITYCurrent
Other Events
Item 8.01 Other Events. On November 14, 2025, the Company issued a press release, a copy of which is attached to this Form 8-K as Exhibit 99.1, announcing results for the periods ended September 30, 2025. On November 14, 2025, the Company issued a press release, a copy of which is attached to this Form 8-K as Exhibit 99.2, announcing the Company’s receipt of an Innovative Technology designation from Vizient®.
Company context
Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint® needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general line distributors.
Current securities
Disclosure sections
Item 8.01Item 8.01 - Other Events
Filed exhibits (2)
EX-99.2 3 tm2531255d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Retractable Technologies, Inc. Receives Innovative Technology Designation from Vizient for EasyPoint Blood Collection Tube Holder with Needle LITTLE ELM, TEXAS, November 14, 2025 - Retractable Technologies, Inc. (NYSE American: RVP) announces its EasyPoint® Blood Collection Tube Holder with Needle has received an Innovative Technology designation from Vizient®, the largest healthcare performance improvement company in the country. Each year, healthcare experts serving on one of Vizient’s client-led councils review select products and technologies for their potential to enhance clinical care, patient safety, healthcare worker safety or to improve business operations of healthcare organizations. Innovative Technology designations are awarded to previously contracted products to signal healthcare providers the impact of these innovations on patient care and business models of healthcare organizations. RTI’s innovative EasyPoint Blood Collection Tube Holder (BCTH) with Needle uses automated retraction to provide instant safety by allowing for in-vein activation, proven to effectively reduce exposure to the contaminated…
Open exhibit ↗